Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2004

01-11-2004 | Original Article

Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats

Authors: Ibrahim Yildirim, Ahmet Korkmaz, Sukru Oter, Ayhan Ozcan, Emin Oztas

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2004

Login to get access

Abstract

Purpose

The aim of this study was to evaluate whether combination of antioxidants and mesna may prevent cystitis induced by cyclophosphamide better than mesna alone.

Materials and methods

A total of 46 male Spraque-Dawley rats were divided into six groups. Five groups received single dose of cyclophosphamide (CP, 100 mg/kg) intraperitoneally with the same time intervals: group 2 received CP only, group 3 received mesna (21.5 mg/kg for three times), group 4 beta-carotene (20 mg/kg for two times) and mesna, group 5 received alpha-tocopherol (20 mg/kg for two times) and mesna, and group 6 received melatonin (5 mg/kg for two times) and mesna on the day of CP injection. Group 1 served as control.

Results

CP injection resulted in severe cystitis. Mesna has showed meaningful but not full protection against CP toxicity. Although beta-carotene did not show any additional beneficial effect when combined with mesna, alpha-tocopherol and especially melatonin with mesna resulted full protection that the pathologist, blinded to the slides, could not differ from sham control.

Conclusion

Oxidants may be important in the pathogenesis of CP-induced cystitis. Melatonin and alpha-tocopherol may help to ameliorate bladder damage along with other drugs such as mesna and diuretics.
Literature
1.
Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 271C:1424–1437
2.
Brock N, Pohl J, Stekar J (1981) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. I. Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer 17(6):595–607CrossRefPubMed
3.
Crow JP, Beckman JS (1996) The importance of superoxide in nitric oxide-dependent toxicity: evidence for peroxynitrite-mediated injury. Adv Exp Med Biol 387:147–161PubMed
4.
Cuzzocrea S, Reiter RJ (2001) Pharmacological action of melatonin in shock, inflammation, and ischemia/reperfusion injury. Eur J Pharm 426:1–10CrossRef
5.
Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL, Szabo C (1997) Melatonin is a scavenger of peroxynitrite. Life Sci 60:169–174CrossRef
6.
Gilbert CJ, Petros WP, Vredenburgh J, Hussein A, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry D, McKinstry C, Peters WP (1998) Pharmacokinetic interaction between ondanstetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42:497–503CrossRefPubMed
7.
Goren MP, McKenna LM, Goodman TL (1997) Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother Pharmacol 40:371–375CrossRefPubMed
8.
Gray KJ, Engelmann UH, Johnson EH, Fishman IJ (1986) Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (cytoxan) therapy. J Urol 133:497–500
9.
Korkmaz A, Oter S, Deveci S, Ozgurtas T, Topal T, Sadir S, Bilgic H (2003) Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol 170:2498–2502PubMed
10.
Kurovski V, Wagner T (1997) Urinary excretion of ifosfamide, 4-hidroxyfosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol 39:431–439CrossRefPubMed
11.
Maharaj DS, Anoopkumar-Dukie S, Glass BD, Antunes EM, Lack B, Walker RB, Daya S (2002) The identification of the UV degradants of melatonin and their ability to scavenge radicals. J Pineal Res 32:257–261CrossRefPubMed
12.
Mates JM, Perez-Gomez P, Nunez de Castro I (1999) Antioxidant enzymes and human disease. Clin Biochem 32:595–603CrossRefPubMed
13.
Muijsers RB, Folkerts G, Henricks PAJ, Hashjin GS, Nijkamp FP (1997) Peroxynitrite: a two faced metabolite of nitric oxide. Life Sci 60:1833–1845CrossRefPubMed
14.
Olson JA (1993) Molecular actions of carotenoids. Ann N Y Acad Sci 691:156–166PubMed
15.
Oter S, Korkmaz A, Oztas E, Yildirim I, Topal T, Bilgic H (2004) Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol Res 32:185–189CrossRefPubMed
16.
Ribeiro RA, Feritas HC, Campos MC, Santos CC, Figueiredo FC, Brito GA, Cunha FQ (2002) Tumor necrosis factor-α and interleukin-1β mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J Urol 67(5):2229–2234CrossRef
17.
Szabo C (1996) The pathophysiological role of role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 6:79–88PubMed
18.
Virag L, Szabo E, Gergely P, Szabo C (2003) Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 141:113–124CrossRef
19.
West NJ (1997) Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 17(4):696–706PubMed
Metadata
Title
Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats
Authors
Ibrahim Yildirim
Ahmet Korkmaz
Sukru Oter
Ayhan Ozcan
Emin Oztas
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2004
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0822-1

Other articles of this Issue 5/2004

Cancer Chemotherapy and Pharmacology 5/2004 Go to the issue

Original Article

Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma

Original Article

Cyclooxygenase inhibitors and thalidomide ameliorate vincristine-induced hyperalgesia in rats

Original Article

HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells

Original Article

A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer

Original Article

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

Original Article

Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits